MANE · Veradermics, Inc
$102.82
-2.50 (-2.37%)
At close · Aug 21
Going-concern doubt
— cleared Aug 11, 2026
The latest filing no longer states the doubt (first flagged May 12, 2026).
View the 10-Q filed Aug 11, 2026Market Cap
$4.32B
Shares
41.78M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$102.82
Open$105.18
Day$102.52–108.87
Available close range$37.03–129.74
Avg vol 30d789K
Short int4.8M · 11.5% float · 6.9d
Short vol60%
Last earningsAug 11, 2026
DataFeb 2026–Aug 2026
Filing10-Q · Aug 11
The closing range uses available history since Feb 4, 2026; less than a full year is stored.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 11, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Strong
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.1 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 50-day avg
−7%
below
RSI (14)
43
neutral
MACD trend
Negative
52-week position
71%
mid-range
Momentum
relative strength
1-month return
−6%
trailing
6-month return
+121%
trailing
Relative strength
+109%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
+101% holders QoQ · +96 funds added
Insider flow
Distributing
Net -$91.1M over 90 days · 100% sells
Short interest
Rising
11.54% of float · ▲ +22.5% MoM · 6.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
163 holders — 13F breadth
Squeeze score
71
high risk · 0–100
Fundamentals
EPS growth
−202%
Y/Y
Free cash flow
$-71.6M
Balance sheet
$21.8M
net cash
Quant / Vol
risk profile
Volatility
100%
annualized · 1-yr
Max drawdown
−21%
past year
ATR
7.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 50-day avg
−7%
Bearish
RSI (14)
43
Neutral
MACD trend
Negative
Bearish
52-week position
71%
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
+101% holders QoQ · +96 funds added
Insider flow
Distributing
Net -$91.1M over 90 days · 100% sells
Short interest
Rising
11.54% of float · ▲ +22.5% MoM · 6.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
163 holders — 13F breadth
Price context
position in its available closing range
Range low $37
Now $103 · 71%
Range high $130
vs 50-day avg -7%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MANE
this stock
Veradermics, Inc
|
$4.32B | — | — | — | 11.5% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +20.9% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$85.87B | +8.1% | +20.8% | 20.8 | 3.3% |
|
ARGX
Argenx SE
|
$64.56B | +23.6% | — | — | 2.1% |
|
CSLLY
Csl Ltd
|
$58.31B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MANE | -8.8% | -6.1% | +120.6% | -2.1% | — |
| SPY | -1.4% | +3.6% | +11.6% | +2.5% | +12.3% |
| vs SPY | -7.4% | -9.7% | +109.0% | -4.6% | — |
Key facts
CIK
1827635
CUSIP
922967104
13F (30d)
161 filings
159 filers
Visit website
Investor relations